The document describes two approaches to drug discovery: the traditional approach and the SWITCH drug re-profiling approach. The traditional approach involves lengthy timelines of 0.5-6 years across target identification, validation, lead identification, candidate optimization, pre-clinical trials, and clinical trials. The SWITCH approach aims to shorten timelines by mining existing drug data to identify new uses for existing drugs and performing a clinical proof of concept trial within 0.5-1 year on a re-profiled drug.